Drugs to treat rheumatoid arthritis may have cardiovascular benefitsBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39517.379977.DB (Published 13 March 2008) Cite this as: BMJ 2008;336:580
- Janice Hopkins Tanne
- 1New York
An international study of 4363 patients with rheumatoid arthritis has shown that use of almost all disease modifying agents reduces cardiovascular events (Arthritis Research and Therapy 2008;10:R30; doi: 10.1186/ar2383).
The study, which looked at disease modifying agents including methotrexate, leflunomide, glucocorticoids, sulfasalazine, and tumour necrosis factor α blockers showed that they reduced these patients’ increased risk of cardiovascular events, perhaps through an anti-inflammatory effect.
The use of malaria drugs and intramuscular gold did not change the risk of cardiovascular disease.
The study, called QUESTRA (questionnaires in standard monitoring of patients with rheumatoid arthritis programme), was led by Antonio Naranjo of the University of Las …
Log in using your username and password
Log in through your institution
Sign up for a free trial